1999
Seminal plasma biochemical markers and their association with semen analysis findings
Diamandis E, Arnett W, Foussias G, Pappas H, Ghandi S, Melegos D, Mullen B, Yu H, Srigley J, Jarvi K. Seminal plasma biochemical markers and their association with semen analysis findings. Urology 1999, 53: 596-603. PMID: 10096390, DOI: 10.1016/s0090-4295(98)00550-0.Peer-Reviewed Original ResearchConceptsVasectomy patientsProstaglandin D synthaseDifferential diagnosisBiochemical markersInsulin-like growth factorPlasma biochemical markersProstate-specific antigenSemen analysis findingsPercentage of motilityPGDS concentrationSeminal plasmaNormal morphologySperm qualitySeminal plasma correlatesPatient ageClinical valueNormal subjectsNonobstructive azoospermiaPatientsClinical groupsBiochemical parametersPlasma correlateProtein 3Immunofluorometric procedureGrowth factor
1995
Prostate-specific antigen immunoreactivity in amniotic fluid.
Yu H, Diamandis E. Prostate-specific antigen immunoreactivity in amniotic fluid. Clinical Chemistry 1995, 41: 204-210. PMID: 7533063, DOI: 10.1093/clinchem/41.2.204.Peer-Reviewed Original ResearchConceptsProtease prostate-specific antigenAmniotic fluidAlpha-fetoproteinGestational ageProstate-specific antigen immunoreactivitySensitive immunofluorometric procedureHigh alpha-fetoproteinHigher PSA concentrationsProstate-specific antigenNormal fetal developmentGrowth factor regulatorSerine protease prostate-specific antigenNonpregnant womenMaternal serumPregnant womenAntigen immunoreactivityBreast tumorsFetal developmentPSA concentrationImmunofluorometric procedurePregnancySignificant correlationWomenAgeSyndrome
1994
Detection of prostate-specific antigen immunoreactivity in breast tumors
Diamandis E, Yu H, Sutherland D. Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Research And Treatment 1994, 32: 301-310. PMID: 7532468, DOI: 10.1007/bf00666007.Peer-Reviewed Original ResearchConceptsProstate-specific antigenPSA immunoreactivityProgesterone receptorP53 tumor suppressor gene productBreast tumorsProstate-specific antigen immunoreactivitySeminal prostate-specific antigenProgesterone receptor-positive tumorsSensitive immunofluorometric procedureReceptor-positive tumorsEarly disease stagesTumor suppressor gene productBreast tumor extractsSuppressor gene productWestern blot analysisDisease stageProstate carcinomaAntigen immunoreactivityTumor extractsTumor specimensClinical practiceImmunoreactivityTumorsYoung womenImmunofluorometric procedureQuantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer
Levesque M, Diamandis E, Yu H, Sutherland D. Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer. Breast Cancer Research And Treatment 1994, 30: 179-195. PMID: 7524772, DOI: 10.1007/bf00666062.Peer-Reviewed Original ResearchConceptsCarcinoembryonic antigenPrognostic indicatorBreast cancerBreast tumorsBiochemical prognostic indicatorsCandidate prognostic indicatorBreast tumor cytosolsSteroid hormone receptorsNegative associationProgesterone receptorTumor cytosolsMutant p53 proteinTumor extractsP53 tumor suppressor gene productSpecific antigenBiochemical parametersObserved associationsHormone receptorsImmunofluorometric procedureStrong positive associationCognate steroid ligandP53 proteinReceptorsStrong negative associationTumor suppressor gene product